UV-spectrum evidence read · GHRH + GHRP stack
CJC-1295 Ipamorelin, reviewed: what the GHRH arm and the ghrelin arm each actually measured in the studies.
Two peptides, two receptors, two very different timescales. Here is the cited record for each half — and the honest gap where the fixed blend was never trialed.
Start here
Here is CJC-1295 Ipamorelin in plain words: it is a research pairing of two lab peptides that both nudge your body to release its own growth hormone (GH). CJC-1295 copies a natural signal called GHRH (the hormone that tells the pituitary gland to make GH). Ipamorelin copies a second, separate signal — it switches on the ghrelin receptor, the same one your stomach uses when you are hungry. Because the two hit different switches, studies show they can produce a bigger GH burst together than either does alone. What people use it for, in research write-ups, is body composition, recovery, and sleep. But honesty first: neither peptide is FDA-approved, and the exact mixed pair has never been tested in a controlled human trial — every combined claim is borrowed from each peptide's own studies. What people report, including the downsides, is on the effects page.
What the single-peptide studies have shown
Start with the headline number. A single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH 2- to 10-fold for six or more days and IGF-1 (a growth factor the liver makes when GH rises) 1.5- to 3-fold for nine to eleven days in healthy adults; after repeated doses IGF-1 stayed above baseline up to 28 days [1]. That is the CJC-1295 half doing its job: a long, steady lift of the GH/IGF-1 axis.
The ipamorelin half is the precise one. Ipamorelin was the first selective GH secretagogue — at doses more than 200 times the amount needed to release GH, it still did not push ACTH or cortisol (two stress hormones) above normal, while matching the GH punch of older peptides like GHRP-6 in swine [2]. Clean signal, one job.
Put a GHRH-type signal and a ghrelin-type signal together and they add up to more than the sum of their parts. In normal men, submaximal GH-releasing-peptide doses combined with GHRH released GH synergistically, the two acting through independent mechanisms [3]. That 1990 human result — not the mixed vial sold today — is the real mechanistic case for pairing them. This is the CJC-1295 Ipamorelin research the rest of the site digs into.
Two receptors, two timescales — keep them straight
The two halves do not run on the same clock, and that matters. CJC-1295 with DAC (a Drug Affinity Complex — a tiny chemical handle that latches onto albumin, a protein in your blood) sticks around for days [1][5]. Ipamorelin fires a single short GH pulse and clears within a couple of hours [2]. There is also a no-DAC version of CJC-1295 — often called Mod GRF (1-29) — that skips the albumin handle and lasts only about thirty minutes [5].
Why spell this out? Because pairing a multi-day peptide with a short-acting one means the neat pulse-on-pulse synergy seen in the literature does not automatically describe the mixed vial people actually use. The combination has a name and a following; it does not have a trial.
What this site is — and is not
This is an editorial digest. We read the published CJC-1295 Ipamorelin literature and translate it into plain English, with every number tied to a study you can check on the references page. We are not a clinic, we sell nothing, and we give no dosing instructions.
Want the cited upsides and downsides people describe? See the effects page. Want the research-context numbers — doses studied, half-lives, routes? That is on the dosing-research page. Curious how the GHRH arm stacks up against an approved cousin? Read ipamorelin vs tesamorelin. And the reported gains people chase are catalogued on the cjc 1295 ipamorelin benefits page — reported, labeled, and kept honest.